Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML3156

Sigma-Aldrich

ALW-II-41-27

≥98% (HPLC)

Sinónimos:

ALW-II-247, N-(5-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylcarbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide, N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]benzamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C32H32F3N5O2S
Número de CAS:
1186206-79-0
Peso molecular:
607.69
Número MDL:
MFCD25372028
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

100

Análisis

≥98% (HPLC)

formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

O=C(NC1=CC=C(CN2CCN(CC)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(NC(C4=CC(C5=CC=CS5)=CN=C4)=O)=C3

InChI

1S/C32H32F3N5O2S/c1-3-39-10-12-40(13-11-39)20-23-8-9-26(17-27(23)32(33,34)35)37-30(41)22-7-6-21(2)28(16-22)38-31(42)25-15-24(18-36-19-25)29-5-4-14-43-29/h4-9,14-19H,3,10-13,20H2,1-2H3,(H,37,41)(H,38,42)

Clave InChI

HYWXBDQAYLPMIX-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

ALW-II-41-27 is an RG-25 (RG25) structural analog that exhibits enhanced type II kinase inhibitor activity against ephrin type-A receptor 2/EphA2/ECK (IC50 = 11 nM vs 770 nM with NG25) by targeting the ATP-binding pocket and an allosteric site next to the “DFG” motif. ALW-II-41-27 inhibits constitutive and ephrin A1-induced EphA2 tyrosine phosphorylation (0.1-1 μM; H358), effectively suppressing EphA2-dependent cancer survival in vitro (0.1-1 μM for 72 hrs; NSCLC) and xenograft tumor growth in mice in vivo (15-30 mg/kg b.i.d. i.p.; H358 NSCLC & A375 melanoma). Note: ALW-II-41-27 and RG-25 (RG25) display very similar kinase-targeting profiles with EphA2 being a notable exception, RG25 can therefore serve as a control for ALW-II-41-27 when probing EphA2-mediated cellular functions.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Katherine R Amato et al.
Cancer research, 76(2), 305-318 (2016-01-09)
Despite the success of treating EGFR-mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternative mechanisms
Katherine R Amato et al.
The Journal of clinical investigation, 124(5), 2037-2049 (2014-04-10)
Genome-wide analyses determined previously that the receptor tyrosine kinase (RTK) EPHA2 is commonly overexpressed in non-small cell lung cancers (NSCLCs). EPHA2 overexpression is associated with poor clinical outcomes; therefore, EPHA2 may represent a promising therapeutic target for patients with NSCLC.
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai, et al.
ACS chemical biology, 10, 2687-2696 (2018)
Ying Xi et al.
Nature cell biology, 19(8), 904-914 (2017-07-25)
After influenza infection, lineage-negative epithelial progenitors (LNEPs) exhibit a binary response to reconstitute epithelial barriers: activating a Notch-dependent ΔNp63/cytokeratin 5 (Krt5) remodelling program or differentiating into alveolar type II cells (AEC2s). Here we show that local lung hypoxia, through hypoxia-inducible
Marialuisa Moccia et al.
PloS one, 10(6), e0128364-e0128364 (2015-06-06)
Oncogenic mutation of the RET receptor tyrosine kinase is observed in several human malignancies. Here, we describe three novel type II RET tyrosine kinase inhibitors (TKI), ALW-II-41-27, XMD15-44 and HG-6-63-01, that inhibit the cellular activity of oncogenic RET mutants at
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico